Release Summary

Combination of Incyte’s Epacadostat plus Merck’s KEYTRUDA (pembrolizumab) Demonstrates Activity in Clinical Trial of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Incyte Corporation and Merck